• SeekInCure®

    The first-in-class blood-based pan-cancer recurrence monitoring test

    SeekCure® is applied to monitoring cancer recurrence and risk evaluation for post-op cancer patients. By monitoring the variation of cancer genome in cell-free DNA (cfDNA) of post-op cancer patients continually, combined with plasma protein markers, equipping big data and artificial intelligence, it generates cancer recurrence index (CRI) .

    A panoramic view of cancer genomic landscape

    cfDNA detection via NGS drawing the view of cancer genomic landscape

    Cutting-edge multivariate algrithm

    Genomics combined with proteomics,capturing the signal of cancer recurrence

    Multidimensional fingerprint

    CNA, Fragmentation and protein markers discovering the early cancer recurrence

    Big date and Artificial intelligence

    CRI model based on machine learning evaluating the risk of cancer recurrence precisely

    Specifications

    Indicated subjects: post-surgery cancer patients
    Sample requirement: 10ml peripheral blood

    TAT: 10 working days

    Result readout: CRI (cancer recurrence index)
    Sampling time:

  •  

    Test Workflow

     

    1

    Pre-test inquiry

    2

    Informed consent

    3

    Blood-draw

    4

    Testing

    5

    Analyzing + Interpretation

    6

    Reporting

    7

    Post-test consultation

    所有文章
    ×

    ©2018 SeekIn Cancer. All Rights Reserved.